These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 580696)

  • 1. Comments on the proposed change in FDA's trade secrets policy.
    Hansen RW
    Am J Pharm Sci Support Public Health; 1977; 149(5):133-7. PubMed ID: 580696
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug industry trying to change FDA's slow but sure policy.
    Demkovich LE
    Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA's consideration of Codex Alimentarius standards in light of international trade agreements.
    Sikes L
    Food Drug Law J; 1998; 53(2):327-35. PubMed ID: 10346688
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA's aseptic processing: proposed regulation.
    Barr DB
    J Parenter Sci Technol; 1993; 47(2):57-9. PubMed ID: 8515345
    [No Abstract]   [Full Text] [Related]  

  • 5. Keeping prescription drug advertising honest. FDA's watchful eye.
    Welsh JS
    Am Pharm; 1980 May; NS20(5):40-4. PubMed ID: 7395709
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's role in drug product recalls.
    Crawford SY
    Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA/CVM's Compliance Policy Guide on compounding of drugs.
    J Am Vet Med Assoc; 1996 Dec; 209(12):2025-9. PubMed ID: 8960175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FDA's restrictions against prescription drug advertising: more hindrance than help.
    Lorman AJ
    Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942
    [No Abstract]   [Full Text] [Related]  

  • 9. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 10. The FDA's critical path initiative: a brief introduction.
    Coons SJ
    Clin Ther; 2009 Nov; 31(11):2572-3. PubMed ID: 20110002
    [No Abstract]   [Full Text] [Related]  

  • 11. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 12. Knowledge is power: legislative control of drug industry trade secrets.
    O'Reilly JT
    Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981
    [No Abstract]   [Full Text] [Related]  

  • 13. Update of FDA's Critical Path Initiative.
    Khleif S
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):173-4. PubMed ID: 19398939
    [No Abstract]   [Full Text] [Related]  

  • 14. Court is asked to invalidate the Food and Drug Administration's (FDA's) "pediatric rule".
    Maloney DM
    Hum Res Rep; 2002 Dec; 17(12):8. PubMed ID: 12731500
    [No Abstract]   [Full Text] [Related]  

  • 15. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA's counsel accused of being too close to drug industry.
    Lenzer J
    BMJ; 2004 Jul; 329(7459):189. PubMed ID: 15271811
    [No Abstract]   [Full Text] [Related]  

  • 17. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA's reaction to corporate compliance audits.
    Shroff AP
    Food Drug Law J; 1996; 51(2):221-3. PubMed ID: 11820199
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulatory research. A centennial letdown for FDA's biologics group.
    Agnew B
    Science; 2002 Nov; 298(5599):1704-5. PubMed ID: 12459566
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA's interferon-beta decision reignites orphan debate.
    Marshall A
    Nat Biotechnol; 1999 Apr; 17(4):324-5. PubMed ID: 10207871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.